| Autor: |
Almeida Furquim de Camargo B; School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil., Fonseca-Santos B; Faculty of Pharmaceutical Sciences, Campinas State University (UNICAMP), Campinas, Brazil., Gonçalves Carvalho S; School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil., Corrêa Carvalho G; School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil., Delello Di Filippo L; School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil., Sousa Araújo VH; School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil., Lobato Duarte J; School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil., Polli Silvestre AL; School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil., Bauab TM; School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil., Chorilli M; School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, Brazil. |
| Abstrakt: |
Infectious diseases are still public health problems. Microorganisms such as fungi, bacteria, viruses, and parasites are the main causing agents related to these diseases. In this context, the search for new effective strategies in prevention and/or treatment is considered essential, since current drugs often have side effects or end up, causing microbial resistance, making it a serious health problem. As an alternative to these limitations, nanotechnology has been widely used. The use of lipid-based drug delivery nanosystems (DDNs) has some advantages, such as biocompatibility, low toxicity, controlled release, the ability to carry both hydrophilic and lipophilic drugs, in addition to be easel scalable. Besides, as an improvement, studies involving the conjugation of signalling molecules on the surfaces of these nanocarriers can allow the target of certain tissues or cells. Thus, this review summarizes the performance of functionalized lipid-based DDNs for the treatment of infectious diseases caused by viruses, including SARS-CoV-2, bacteria, fungi, and parasites. |
